A review of AbobotulinumtoxinA (Dysport).

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M. Sykes, Heidi A. Waldorf

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.

Original languageEnglish (US)
Pages (from-to)13S-7S
JournalUnknown Journal
Volume33
Issue number1 Suppl
DOIs
StatePublished - Mar 2013

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'A review of AbobotulinumtoxinA (Dysport).'. Together they form a unique fingerprint.

  • Cite this

    Lorenc, Z. P., Kenkel, J. M., Fagien, S., Hirmand, H., Nestor, M. S., Sclafani, A. P., Sykes, J. M., & Waldorf, H. A. (2013). A review of AbobotulinumtoxinA (Dysport). Unknown Journal, 33(1 Suppl), 13S-7S. https://doi.org/10.1177/1090820X12474632